Oral Apixaban Valid, Patient-Friendly for Cancer-Associated Venous Thromboembolism
A new study suggests apixaban may be a potential treatment for cancer-associated venous thromboembolism, with possible variation in outcomes by cancer site.
Thromboembolism
Direct Oral Anticoagulants as Effective as Vitamin K Antagonists for Thromboembolic Events With Myeloproliferative Neoplasms
The efficacy and safety of direct oral anticoagulants and vitamin K antagonists in the treatment of ATEs/VTEs in patients with MPNs was compared.
Venous Thromboembolism Risk Steadily Increasing in Cancer
The risk for venous thromboembolism is steadily increasing among patients with cancer compared with the general population.
Venous Thromboembolism Rates in Patients With SARS-CoV-2 Infection
In a new study, researchers reported on the frequency of VTE among more than 6000 patients who tested positive for infection with SARS-CoV-2.
Notable Variation Exists in the Treatment of Serious VTE Events in Pediatric Leukemia
There might be notable variations among hematology, oncology, and bone marrow transplant practitioners when treating thrombotic events in children with leukemia.
Rivaroxaban May Be a Suitable Alternative to Low-Molecular Weight Heparin in Cancer-Associated Thrombosis
Among some patients with cancer-associated thrombosis, rivaroxaban may be a viable alternative to low-molecular-weight heparin.
Molecular Profiling Can Assess Risk for Myeloproliferative Neoplasms With Splanchnic Vein Thrombosis
Researchers sought to markers that could identify high risk for splanchnic vein thrombosis among patients with MPNs.
Understanding the Association Between COVID-19, Thromboembolism, and Therapeutic Anticoagulation
In expanded research, investigators studied the effects of therapeutic and prophylactic anticoagulation treatment in hospitalized patients with COVID-19.
Risk of Thrombosis With Treatments for Newly Diagnosed Multiple Myeloma
Despite thromboprophylaxis, patients who have newly developed multiple myeloma are at an “unacceptably high VTE risk”, study results suggest.
Clotting and COVID: New Guidelines in the Works to Treat Coagulopathies in Patients With COVID-19
Growing concerns about thromboembolic comorbidities in patients with COVID-19 is leading ASH to create clinical practice guidelines to treat this patient population.
- Loading...
Loading...
Next post in Hematologic Cancers
Loading... 
Loading...